ArticleBMC endocrine disorders2025
HMGB1 and TLR4 as biomarkers for osteoporosis risk in type 2 diabetes mellitus: a cross-sectional study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study explored the application value of high mobility group box 1 (HMGB1) and toll-like receptor 4 (TLR4) levels in the diagnosis of type 2 diabetes mellitus (T2DM) with osteoporosis (OP).
methodsThis was a cross-sectional study of 126 patients. The patients with T2DM was stratified into the following three subgroups: normal bone mass, osteopenia, and OP. Comparative analyses of general data and biochemical indices were performed, and Pearson's correlation was used to assess the relationship among HMGB1, TLR4 levels, and bone mineral density (BMD). Multivariate logistic regression identified risk factors in patients with T2DM. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of HMGB1 and TLR4 levels for OP in patients with T2DM.
resultsHMGB1 and TLR4 levels were significantly higher in the OP group than in the normal bone mass and osteopenia groups (p < 0.05). Pearson's correlation analysis revealed a negative association among BMD, HMGB1, and TLR4 levels. Multivariate logistic regression analysis identified Mg, HMGB1, and TLR4 as significant OP risk factors for T2DM. ROC curve analysis demonstrated that the areas under the curve for HMGB1 and TLR4 in predicting OP in patients with T2DM were 0.828 and 0.854, respectively, with respective sensitivities of 79.4% and 94.1% and respective specificities of 78.3% and 58.7%.
conclusionsSerum HMGB1 and TLR4 levels may be potential biomarkers for OP in patients with T2DM.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.